Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

105.49 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >

Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

August 08, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance ↗

August 06, 2025

Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 06, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum ↗

August 06, 2025

Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.

Via Chartmill

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock ↗

May 09, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Preview: Mirum Pharmaceuticals's Earnings ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views ↗

November 13, 2024

Via Benzinga

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish ↗

April 14, 2025

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Via Stocktwits

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol ↗

February 21, 2025

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Outlook For Mirum Pharmaceuticals ↗

November 11, 2024

Via Benzinga

We Tested Top Stocks; Here’s What’s Best For Your Money ↗

November 10, 2024

Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities.

Via Talk Markets

Analyst Expectations For Mirum Pharmaceuticals's Future ↗

October 11, 2024

Via Benzinga

Analyst Ratings For Mirum Pharmaceuticals ↗

May 09, 2024

Via Benzinga

Analyst Ratings For Mirum Pharmaceuticals ↗

April 17, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals ↗

March 18, 2024

Via Benzinga

Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know ↗

February 29, 2024

Via Benzinga

MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024 ↗

August 07, 2024

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 18, 2024

Via Benzinga

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 17, 2024

Via Benzinga

Mirum Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 17, 2024

Via Benzinga

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies ↗

June 17, 2024

Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and...

Via Benzinga

Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday ↗

June 17, 2024

Via Benzinga

MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying ↗

March 28, 2024

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Via Benzinga

FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy ↗

March 14, 2024

FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

Headline News about Mirum Pharmaceuticals, Inc. - common stock

Starting at $3.75/week.

Subscribe Today